

INFORMAZIONI PERSONALI

Salvatore Lopez

✉ salvatore.lopez@istitutotumori.mi.it

<https://www.linkedin.com/in/salvatore-lopez-279b5a142/>

Sesso Maschile | Data di nascita 26/06/aaaa | Nazionalità Italiana

ESPERIENZA
PROFESSIONALE

2019 – presente

Dirigente medico

SC. Ginecologia Oncologica Istituto Tumori Milano

ISTRUZIONE E FORMAZIONE

02/2018 – 03/2019

Postdoctoral Research Fellow, Gynecologic Oncology Laboratory

Yale University, School of Medicine, New Haven CT, USA. (Prof. Alessandro Santin)

2017-2019

Dottorando in Oncologia molecolare e traslazionale e tecniche chirurgiche innovative

Università Magna Graecia di Catanzaro

08/2017 – 01/2018

Medico volontario – Divisione di Ginecologia Oncologica (Prof. Greggi)

Istituto Tumori di Napoli "Pascale"

May-17

Observership Divisione di Ginecologia Oncologica

University of Toronto, Canada

2012-2017

Specializzazione in Ginecologia e Ostetricia

Policlinico Universitario Campus Bio Medico di Roma

03/2013 – 12/2014

Postdoctoral Research Fellow, Gynecologic Oncology Laboratory

Yale University, School of Medicine, New Haven CT, USA. (Prof. Alessandro Santin)

2009-2011

Tirocinio curricolare, Reparto Ginecologia

Policlinico Universitario Campus Bio Medico di Roma

2008-2011

Laurea in Medicina e Chirurgia

Facoltà di Medicina e Chirurgia. Policlinico Universitario Campus Bio Medico di Roma

ULTERIORI INFORMAZIONI

Pubblicazioni

1. Luvero D, Plotti F, Aloisia A, Montera R, Terranova C, Carlo De Cicco Nardone, Scaletta G, Lopez S, Miranda A, Capriglione S, Gatti A, Pierluigi Benedetti Panici, Angioli R. *Ovarian cancer relapse: From the latest scientific evidence to the best practice.* Crit Rev Oncol Hematol. 2019 May 29;140:28-38. doi:10.1016/j.critrevonc.2019.05.014. [Epub ahead of print] Review. PubMed PMID:31176270.
2. Filippini M, Farinelli M, Lopez S, Ettore C, Gulino FA, Capriglione S. *Postpartum perineal pain: may the vaginal treatment with CO(2) laser play a key-role in this challenging issue?* J Matern Fetal Neonatal Med. 2019 Jun 4:1-181. doi: 10.1080/14767058.2019.1628208. [Epub ahead of print] PubMed PMID: 31164016.
3. Plotti F, Guzzo F, Schirò T, Terranova C, De Cicco Nardone C, Montera R, Luvero D, Scaletta G, Lopez S, Capriglione S, Benedetti Panici P, Angioli R. *Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients.* Int J Gynecol Cancer. 2019 Apr 16. pii: ijgc-2019-000211. doi: 10.1136/ijgc-2019-000211. [Epub ahead of print] PubMed

PMID: 30992329.

4. Cocco E, Lopez S, Santin AD, Scaltriti M. *Prevalence and role of HER2 mutations in cancer*. *Pharmacol Ther*. 2019 Apr 2. pii: S0163-7258(19)30057-9. doi: 10.1016/j.pharmthera.2019.03.010. [Epub ahead of print] Review. PubMed PMID: 30951733.
5. Angioli R, Casciello M, Lopez S, Plotti F, Minco LD, Frati P, Fineschi V, Panici PB, Scaletta G, Capriglione S, Miranda A, Feole L, Terranova C. *Assessing HPV vaccination perceptions with online social media in Italy*. *Int J Gynecol Cancer*. 2019 Mar;29(3):453-458. doi: 10.1136/ijgc-2018-000079. Epub 2019 Jan 10. PubMed PMID: 30630890.
6. Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. *PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers*. *Gynecol Oncol*. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7. PubMed PMID: 30630630; PubMed Central PMCID: PMC6430698.
7. Lopez S, Zeybek B, Santin AD. *Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management*. *Oncotarget*. 2018 Nov 30;9(94):36652-36653. doi: 10.18632/oncotarget.26413. eCollection 2018 Nov 30. PubMed PMID: 30613348; PubMed Central PMCID: PMC6291176.
8. Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. *Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors*. *Proc Natl Acad Sci U S A*. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24. Erratum in: *Proc Natl Acad Sci U S A*. 2019 Mar 19;116(12):5829. PubMed PMID: 30584090; PubMed Central PMCID: PMC6329978.
9. Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, Vitagliano A, Noventa M, La Rosa VL, Sapia F, Valenti G, Rapisarda AMC, Peterlunger I, Rossetti D, Laganà AS. *Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition*. *Arch Gynecol Obstet*. 2019 Feb;299(2):299-315. doi: 10.1007/s00404-018-5006-z. Epub 2018 Dec 12. Review. PubMed PMID: 30542793.
10. Zeybek B, Lopez S, Santin AD. *BET inhibitors: Betting on improved outcomes in uterine serous carcinoma*. *Oncotarget*. 2018 Oct 26;9(84):35470-35471. doi: 10.18632/oncotarget.26245. eCollection 2018 Oct 26. PubMed PMID: 30464799; PubMed Central PMCID: PMC6231456.
11. Capriglione S, Manzano A, Gulino FA, Lopez S. *Management of gynecological cancer in pregnant patients*. *Minerva Ginecol*. 2019 Apr;71(2):133-145. doi: 10.23736/S0026-4784.18.04324-1. Epub 2018 Oct 11. PubMed PMID: 30318875.
12. Menderes G, Lopez S, Han C, Altwerger G, Gysler S, Varughese J, Schwartz PE, Santin AD. *Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it*. *Discov Med*. 2018 Aug;26(141):39-50. Review. PubMed PMID: 30265854.
13. Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD. *Novel targeted therapies in ovarian and uterine carcinosarcomas*. *Discov Med*. 2018 Jun;25(140):309-319. Review. PubMed PMID: 30021104.
14. Capriglione S, Plotti F, Terranova C, Gulino FA, Di Guardo F, Lopez S, Scaletta G, Angioli R. *Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature*. *J Matern Fetal Neonatal Med*. 2018 Sep 10:1-10. doi: 10.1080/14767058.2018.1495191. [Epub ahead of print] PubMed PMID: 29954233.

15. Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. *Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer*. Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25. PubMed PMID: 29941483; PubMed Central PMCID: PMC6168417.
16. Vitale SG, Capriglione S, Peterlunger I, La Rosa VL, Vitagliano A, Noventa M, Valenti G, Sapia F, Angioli R, Lopez S, Sarpietro G, Rossetti D, Zito G. *The Role of Oxidative Stress and Membrane Transport Systems during Endometriosis: A Fresh Look at a Busy Corner*. Oxid Med Cell Longev. 2018 Mar 21;2018:7924021. doi: 10.1155/2018/7924021. eCollection 2018. Review. PubMed PMID: 29743986; PubMed Central PMCID: PMC5883985.
17. Montera R, Scaletta G, Plotti F, Lopez S, Luvero D, Capriglione S, Aloisi A, Gatti A, De Cicco Nardone C, Carassiti R, Terranova C, Angioli R. *The role of macrolastique implantation in the management of occult urinary stress incontinence*. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:124-128. doi: 10.1016/j.ejogrb.2018.04.014. Epub 2018 Apr 21. PubMed PMID: 29704816.
18. Plotti F, Capriglione S, Scaletta G, Luvero D, Lopez S, Nastro FF, Terranova C, De Cicco Nardone C, Montera R, Angioli R. *Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey*. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:51-56. doi: 10.1016/j.ejogrb.2018.03.044. Epub 2018 Apr 7. PubMed PMID: 29660578.
19. Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, Lopez S, Montera R, Gatti A, Serra GB, Benedetti Panici P, Terranova C. *Hormone replacement therapy in cancer survivors: Utopia?* Crit Rev Oncol Hematol. 2018 Apr;124:51-60. doi: 10.1016/j.critrevonc.2018.02.005. Epub 2018 Feb 8. Review. PubMed PMID: 29548486.
20. Montera R, Miranda A, Plotti F, Terranova C, Luvero D, Capriglione S, Scaletta G, Zullo MA, Buscarini M, Lopez S, Gatti A, Schirò T, De Cicco Nardone C, Angioli R. *Anterior colporrhaphy plus inside-out tension-free vaginal tape for associated stress urinary incontinence and cystocele: 10-year follow up results*. Neurourol Urodyn. 2018 Mar;37(3):1144-1151. doi: 10.1002/nau.23439. Epub 2017 Oct 23. PubMed PMID: 29058820.
21. Scaletta G, Plotti F, Luvero D, Capriglione S, Montera R, Miranda A, Lopez S, Terranova C, De Cicco Nardone C, Angioli R. *The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review*. Expert Rev Anticancer Ther. 2017 Sep;17(9):827-839. doi: 10.1080/14737140.2017.1360138. Epub 2017 Aug 3. Review. PubMed PMID: 28756722.
22. Vitale SG, Laganà AS, Capriglione S, Angioli R, La Rosa VL, Lopez S, Valenti G, Sapia F, Sarpietro G, Butticiè S, Tuscano C, Fanale D, Tropea A, Rossetti D. *Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives*. Int J Mol Sci. 2017 May 20;18(5). pii: E1100. doi: 10.3390/ijms18051100. Review. PubMed PMID: 28531111; PubMed Central PMCID: PMC5455008.
23. Luvero D, Plotti F, Lopez S, Scaletta G, Capriglione S, Montera R, Antonelli G, Ciuffreda S, Carassiti R, Oliveti A, Angioli R. *Antiangiogenics and immunotherapies in cervical cancer: an update and future's view*. Med Oncol. 2017 Jun;34(6):115. doi: 10.1007/s12032-017-0972-8. Epub 2017 May 5. Review. PubMed PMID: 28477178.
24. Plotti F, Scaletta G, Capriglione S, Montera R, Luvero D, Lopez S, Gatti A, De Cicco Nardone C, Terranova C, Angioli R. *The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer*. Int J Gynecol Cancer. 2017 May;27(4):696-702. doi: 10.1097/IGC.0000000000000944. PubMed PMID: 28406844.
25. Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. *Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo*. Med Oncol. 2017 May;34(5):91. doi: 10.1007/s12032-017-0956-8. Epub 2017 Apr 10. PubMed PMID: 28397106; PubMed Central PMCID: PMC5896014.
26. Plotti F, Capriglione S, Terranova C, Montera R, Scaletta G, Lopez S, Luvero D, Gianina

- A, Aloisi A, Benedetti Panici P, Angioli R. Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset. *Med Oncol*. 2017 May;34(5):82. doi: 10.1007/s12032-017-0945-y. Epub 2017 Apr 7. PubMed PMID: 28389908.
27. Marino R, Capriglione S, Morosetti G, Di Angelo Antonio S, Miranda A, Pazzola M, Lopez S, Patrizi L, Angioli R, Stella P. *May intraperitoneal irrigation with Betadine improve cesarean delivery outcomes? Results of a 6 years' single centre experience*. *J Matern Fetal Neonatal Med*. 2018 Mar;31(5):670-676. doi: 10.1080/14767058.2017.1293036. Epub 2017 Mar 8. PubMed PMID: 28274149.
28. Luvero D, Plotti F, Capriglione S, Miranda A, Lopez S, Scaletta G, Dell'anna A, Angioli R. *Undescended or absent ovary without uterine anomalies: systematic review and a single center's experience*. *Minerva Ginecol*. 2017 Feb;69(1):35-40. doi: 10.23736/S0026-4784.16.03920-4. Review. PubMed PMID: 28116887.
29. Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. *Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells*. *Mol Cancer Ther*. 2017 Feb;16(2):323-333. doi: 10.1158/1535-7163.MCT-16-0501. Epub 2016 Dec 12. PubMed PMID: 27956521; PubMed Central PMCID: PMC5292071.
30. Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. *Polymerase ϵ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro*. *Gynecol Oncol*. 2017 Jan;144(1):146-152. doi: 10.1016/j.ygyno.2016.11.023. Epub 2016 Nov 26. PubMed PMID: 27894751; PubMed Central PMCID: PMC5183545.
31. Capriglione S, Plotti F, Miranda A, Lopez S, Scaletta G, Moncelli M, Luvero D, De Cicco Nardone C, Terranova C, Montera R, Angioli R. *Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4*. *Expert Rev Anticancer Ther*. 2017 Jan;17(1):9-18. Epub 2016 Dec 12. Review. PubMed PMID: 27892774.
32. Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. *Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition*. *Proc Natl Acad Sci U S A*. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10. PubMed PMID: 27791010; PubMed Central PMCID: PMC5087050.
33. Capriglione S, Plotti F, Montera R, Luvero D, Lopez S, Scaletta G, Aloisi A, Serra GB, Angioli R. *Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial*. *Gynecol Oncol*. 2016 Dec;143(3):584-588. doi: 10.1016/j.ygyno.2016.10.006. Epub 2016 Oct 15. PubMed PMID: 27751589.
34. Luvero D, Plotti F, Capriglione S, Miranda A, Lopez S, Scaletta G, Dell'anna A, Angioli R. *Undescended or absent ovary without uterine anomalies: systematic review and a single-center experience*. *Minerva Ginecol*. 2016 Oct 11. [Epub ahead of print] PubMed PMID: 27727203.
35. Luvero D, Plotti F, Aloisi A, Capriglione S, Ricciardi R, Miranda A, Lopez S, Scaletta G, De Luca G, Benedetti-Panici P, Angioli R. *Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up*. *Med Oncol*. 2016 Oct;33(10):110. doi: 10.1007/s12032-016-0830-0. Epub 2016 Aug 30. PubMed PMID: 27577931.
36. Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. *Dual CCNE1/PIK3CA targeting*

- is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.* Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28. PubMed PMID: 27351214; PubMed Central PMCID: PMC4973158.
37. Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2. PubMed PMID: 27256376.
 38. Angioli R, Lopez S, Aloisi A, Terranova C, De Cicco C, Scaletta G, Capriglione S, Miranda A, Luvero D, Ricciardi R, Montera R, Plotti F. *Ten years of HPV vaccines: State of art and controversies.* Crit Rev Oncol Hematol. 2016 Jun;102:65-72. doi: 10.1016/j.critrevonc.2016.03.020. Epub 2016 Apr 2. Review. PubMed PMID: 27066937.
 39. Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. *PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.* Br J Cancer. 2015 Dec 1;113(11):1641. doi: 10.1038/bjc.2015.388. PubMed PMID: 26625219; PubMed Central PMCID: PMC4705897.
 40. Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. *Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.* J Exp Clin Cancer Res. 2015 Oct 17;34:123. doi: 10.1186/s13046-015-0241-7. PubMed PMID: 26474755; PubMed Central PMCID: PMC4609066.
 41. Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. *Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.* Mol Cancer Ther. 2015 Nov;14(11):2519-26. doi: 10.1158/1535-7163.MCT-15-0383. Epub 2015 Sep 2. PubMed PMID: 26333383; PubMed Central PMCID: PMC4636465.
 42. Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. *PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.* Br J Cancer. 2015 Sep 29;113(7):1020-6. doi: 10.1038/bjc.2015.306. Epub 2015 Sep 1. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1641. PubMed PMID: 26325104; PubMed Central PMCID: PMC4651122.
 43. Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. *Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.* Am J Obstet Gynecol. 2016 Jan;214(1):99.e1-8. doi: 10.1016/j.ajog.2015.08.011. Epub 2015 Aug 10. PubMed PMID: 26272866; PubMed Central PMCID: PMC4698047.
 44. Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. *Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.* Gynecol Oncol. 2015 Oct;139(1):112-7. doi: 10.1016/j.ygyno.2015.08.002. Epub 2015 Aug 8. PubMed PMID: 26260909; PubMed Central PMCID: PMC4587290.
 45. Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. *Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.* Int J Cancer. 2015 Dec 1;137(11):2618-29. doi: 10.1002/ijc.29632. Epub 2015 Aug 18. PubMed PMID: 26060989; PubMed Central PMCID: PMC4573336.
 46. Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD.

- Polymerase ϵ (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. *Gynecol Oncol.* 2015 Jul;138(1):11-7. doi: 10.1016/j.ygyno.2015.04.027. Epub 2015 Apr 27. PubMed PMID: 25931171; PubMed Central PMCID: PMC4469551.
47. Black JD, Lopez S, Cocco E, Schwab CL, English DP, Santin AD. Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers. *Toxins (Basel).* 2015 Apr 1;7(4):1116-25. doi: 10.3390/toxins7041116. Review. PubMed PMID: 25835384; PubMed Central PMCID: PMC4417958.
 48. Angioli R, Capriglione S, Aloisi A, Ricciardi R, Scaletta G, Lopez S, Miranda A, Di Pinto A, Terranova C, Plotti F. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. *Ann Surg Oncol.* 2015 Dec;22(13):4217-23. doi: 10.1245/s10434-015-4534-z. Epub 2015 Mar 26. PubMed PMID: 25808099.
 49. Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. *Tumour Biol.* 2015 Jul;36(7):5505-13. doi:10.1007/s13277-015-3218-4. Epub 2015 Feb 11. PubMed PMID: 25669172; PubMed Central PMCID: PMC5573583.
 50. Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. *Clin Exp Metastasis.* 2015 Jan;32(1):29-38. doi: 10.1007/s10585-014-9688-8. Epub 2014 Nov 15. PubMed PMID: 25398397; PubMed Central PMCID: PMC4310789.
 51. English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. *Cancer.* 2015 Feb 1;121(3):403-12. doi: 10.1002/cncr.29062. Epub 2014 Sep 23. PubMed PMID: 25251053; PubMed Central PMCID: PMC4304922.
 52. Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. *Gynecol Oncol.* 2014 Nov;135(2):312-7. doi: 10.1016/j.ygyno.2014.08.024. Epub 2014 Aug 27. PubMed PMID: 25172762; PubMed Central PMCID: PMC4270135.
 53. Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. *Gynecol Oncol.* 2014 Oct;135(1):142-8. doi: 10.1016/j.ygyno.2014.08.006. Epub 2014 Aug 12. PubMed PMID: 25124161.
 54. English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. *Cancer Med.* 2014 Oct;3(5):1256-65. doi: 10.1002/cam4.274. Epub 2014 Jun 2. PubMed PMID: 24890382; PubMed Central PMCID: PMC4302675.
 55. English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. *Gynecol Oncol.* 2013 Dec;131(3):753-8. doi: 10.1016/j.ygyno.2013.08.033. Epub 2013 Sep 4. PubMed PMID: 24012800.
 56. English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). *Am J*

Obstet Gynecol. 2013 Nov;209(5):465.e1-9. doi: 10.1016/j.ajog.2013.07.020. Epub 2013 Jul 24. PubMed PMID: 23891627.

Dati personali Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".